Department of Head and Neck Surgery, UCLA David Geffen School of Medicine, 10833 Le Conte Ave. 62-132 CHS, Los Angeles, CA, 90095-1624, USA.
Department of Neurosurgery, UCLA David Geffen School of Medicine, Los Angeles, USA.
Pituitary. 2018 Jun;21(3):290-301. doi: 10.1007/s11102-018-0872-8.
Pituitary tumors are the second most common intracranial tumors, however, pituitary carcinoma is a rare clinical entity which represents only 0.1-0.2% of all pituitary tumors. Diagnosis of pituitary carcinoma requires the presence of metastasis. Early identification of pituitary carcinoma is difficult, and only recently have guidelines been published for the treatment of aggressive pituitary tumors. We present two cases from our institution, with a review of other cases available in literature in order to better characterize this rare disease.
A retrospective review of two patients with pituitary carcinoma treated at a tertiary medical center was performed. The MEDLINE database was searched for all cases of pituitary carcinoma. Information for age at diagnosis, sex, pituitary tumor type, latency period from pituitary tumor to presentation of carcinoma, sites of metastasis, number of surgical therapies, radiation and chemotherapy, and survival after diagnosis were collected.
A total of 69 studies were available for review for a total of 72 unique cases. The average age at diagnosis was 46.3 years. The most common tumors were ACTH-secreting (34.7%), Prolactin-secreting (23.6%), and Null Cell (15.3%). The average latency period from pituitary tumor diagnosis to metastasis was 9 years. All patients underwent surgical therapy during their treatment, with an average of 2.76 procedures. The mortality rate was 54.8% with average time to death after diagnosis of approximately 10 months.
Pituitary carcinoma is a rare disease with high mortality rate and is a diagnostic and treatment challenge. Further study is required but is difficult due to its low incidence.
垂体肿瘤是第二常见的颅内肿瘤,然而,垂体癌是一种罕见的临床实体,仅占所有垂体肿瘤的 0.1-0.2%。垂体癌的诊断需要存在转移。早期识别垂体癌较为困难,直到最近才发布了治疗侵袭性垂体肿瘤的指南。我们报告了来自我们机构的两例病例,并对文献中其他病例进行了回顾,以便更好地描述这种罕见疾病。
对在一家三级医疗中心接受治疗的两例垂体癌患者进行了回顾性研究。在 MEDLINE 数据库中搜索了所有垂体癌病例。收集了诊断时的年龄、性别、垂体肿瘤类型、从垂体肿瘤到癌表现的潜伏期、转移部位、手术治疗次数、放疗和化疗以及诊断后生存情况等信息。
共有 69 项研究可用于回顾,共涉及 72 例独特病例。诊断时的平均年龄为 46.3 岁。最常见的肿瘤是 ACTH 分泌瘤(34.7%)、催乳素分泌瘤(23.6%)和无功能细胞瘤(15.3%)。从垂体肿瘤诊断到转移的平均潜伏期为 9 年。所有患者在治疗期间均接受了手术治疗,平均手术次数为 2.76 次。死亡率为 54.8%,诊断后平均死亡时间约为 10 个月。
垂体癌是一种死亡率高的罕见疾病,具有诊断和治疗挑战性。由于发病率低,需要进一步研究,但这很困难。